

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1041-10

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	09/423,109
Filing Date	October 29, 1999
First Named Inventor	Jacques Paris et al.
Art Unit	1616
Examiner Name	QA21, SABINA
Attorney Docket Number	76497-AAJJPW/AG

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ² Number ³ Kind Code ⁴ (if known)	MM-DD-YYYY		
589	}	WO 98/15279	04-16-1998		
		WO 01/30355 A1	05-03-2001		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicants: J. Paris et al
Serial No.: 09/432,109
Filed: October 29, 1999
Exhibit A

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/423,109
		Filing Date	October 29, 1999
		First Named Inventor	Jacques Paris et al.
		Art Unit	1616
		Examiner Name	9421, SAB, HA
Sheet 2	of 2	Attorney Docket Number	76497-AA/JPW/AG

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		French Patent No. 2754179 A1, issued April 10, 1998	
		Canadian Patent No. 1332227, issued October 4, 1994	
SCB		Cano, et al., (1991). "Effect Of Continuous Oestradiolmedroxyprogesterone Administration On Plasma Lipids And Lipoproteins," Maturitas, 13(1):35-42	
		Catherino, et al., (1995). "Nomegestrol Acetate, a Clinically Useful 19-Norprogesterone Derivative Which Lacks Estrogenic...", J. Steroid Biochem. Mol. Biol., 55(2):239-46	
		Fraser, et al., (1991). "The Effects Of The Additional Of Nomegestrol Acetate To Post-Menopausal Oestrogen Therapy," Maturitas, 11(1):21-34	
		Jamin, (1992). "Female Contraception By A Normal Dose Progestogen After 40 Years Of Age. Possible Association...", Rev. Fr. Gynecol. Obstet., 87(6):370-376, English Abstract	
		Sitruk-Ware, (1995). "Pharmacology Of Oral Contraceptives," Rev. Prat., 45 (19):2401-2406, English Abstract	

Examiner Signature	Sabeira N. Qazi	Date Considered	12/21/08
--------------------	-----------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.